Annual report
4323.TEDINET S100TQ3R
Period2023-04-01 → 2024-03-31
Filed2024-06-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 150
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥26.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥23.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥21.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥18.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥18.0bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥2.8bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥2.4bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥2.9bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.5bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.1bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.3bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.0bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.9bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.5bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.3bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥579m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥31m | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥2.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥1.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥20.0bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥17.4bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥15.5bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥12.9bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥13.0bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.3bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥6.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥12.7bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥10.8bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥9.2bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥6.9bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥6.2bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥8.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥7.2bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.5bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥3.9bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.2bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥417m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥761m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥542m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥81m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥87m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥527m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥424m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥281m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥487m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥185m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥85.08 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥72.25 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥56.16 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥26.99 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.44 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥26.98 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥516.08 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥439.03 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥373.43 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥316.49 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥288.52 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 63.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.8% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.9% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.0% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.7% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 17.8% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 17.8% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 16.7% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.9% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | -0.5% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,847 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 1,687 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 1,448 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 1,320 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 1,164 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥20.4bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥18.6bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥17.1bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥15.2bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥14.4bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥2.1bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥1.8bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥2.2bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.1bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.8bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.1bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.1bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.2bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥2.1bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥1.6bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥1.6bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥1000m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥401m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥22m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥17.3bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥15.5bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥14.0bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥11.8bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥12.1bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥5.9bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥5.3bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥11.4bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥10.2bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥8.8bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥6.9bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥6.5bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥5.8bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.9bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥65.82 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.47 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥42.19 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥18.71 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥1.02 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥18.7 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥45 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥32 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥466.42 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥415.93 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥358.96 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥320.15 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥304.85 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 65.9% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.8% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.0% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.0% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 14.9% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.2% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.7% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 0.3% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 12,418,460 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 12,418,460 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 6,209,230 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,612,230 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,612,230 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 1,009 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 926 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 871 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 827 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 753 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 68
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥206m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥206m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥2.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥1.9bn |
| Global Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥44m |
| Global Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥56m |
| Global Businessreportable segment | employees | at 2024-03-31 | 617 pure |
| Global Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥3.4bn |
| Global Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥3.4bn |
| Global Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥70m |
| Global Businessreportable segment | segment assets | at 2024-03-31 | ¥2.4bn |
| Global Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥402m |
| Medical Big Data Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥60m |
| Medical Big Data Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥26m |
| Medical Big Data Businessreportable segment | employees | at 2024-03-31 | 157 pure |
| Medical Big Data Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥2.6bn |
| Medical Big Data Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥2.6bn |
| Medical Big Data Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥3m |
| Medical Big Data Businessreportable segment | segment assets | at 2024-03-31 | ¥2.6bn |
| Medical Big Data Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥686m |
| Package Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥117m |
| Package Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥33m |
| Package Businessreportable segment | employees | at 2024-03-31 | 228 pure |
| Package Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| Package Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| Package Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥6m |
| Package Businessreportable segment | segment assets | at 2024-03-31 | ¥4.0bn |
| Package Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥526m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥196m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥26.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥26.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥206m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥17.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥4.7bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥182m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥182m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥2.0bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥1.7bn |
| Global Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥32m |
| Global Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥54m |
| Global Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥2.7bn |
| Global Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥2.7bn |
| Global Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥50m |
| Global Businessreportable segment | segment assets | at 2023-03-31 | ¥2.1bn |
| Global Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥271m |
| Medical Big Data Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥30m |
| Medical Big Data Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥19m |
| Medical Big Data Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| Medical Big Data Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| Medical Big Data Businessreportable segment | segment assets | at 2023-03-31 | ¥1.6bn |
| Medical Big Data Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥457m |
| Package Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥19m |
| Package Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥28m |
| Package Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥4.5bn |
| Package Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥4.5bn |
| Package Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥42m |
| Package Businessreportable segment | segment assets | at 2023-03-31 | ¥3.6bn |
| Package Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥1.3bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥123m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥163m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥23.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥23.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥182m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥15.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥4.1bn |
| Medical Big Data Businessreportable segment | employees | at 2024-03-31 | 93 pure |
| Package Businessreportable segment | employees | at 2024-03-31 | 223 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,514
| Item | Context | Value | Unit |
|---|---|---|---|
| Provision for directors bonuses | CurrentYearInstant | 133649000 | JPY |
| Provision for loss on construction contracts | Prior1YearInstant | 6801000 | JPY |
| Provision for loss on construction contracts | CurrentYearInstant | 14510000 | JPY |
| Other cl | Prior1YearInstant | 967961000 | JPY |
| Other cl | CurrentYearInstant | 1228837000 | JPY |
| Current liabilities | Prior1YearInstant | 4703978000 | JPY |
| Current liabilities | CurrentYearInstant | 5222954000 | JPY |
| Long term loans payable | Prior1YearInstant | － | JPY |
| Long term loans payable | CurrentYearInstant | 65960000 | JPY |
| Provision for share based remuneration for directors and other officers ncl | Prior1YearInstant | 141759000 | JPY |
| Provision for share based remuneration for directors and other officers ncl | CurrentYearInstant | 155990000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 1110713000 | JPY |
| Net defined benefit liability | CurrentYearInstant | 1087676000 | JPY |
| Asset retirement obligations ncl | Prior1YearInstant | 239628000 | JPY |
| Asset retirement obligations ncl | CurrentYearInstant | 273506000 | JPY |
| Deferred tax liabilities | Prior1YearInstant | 28464000 | JPY |
| Deferred tax liabilities | CurrentYearInstant | 29824000 | JPY |
| Other ncl | Prior1YearInstant | 373011000 | JPY |
| Other ncl | CurrentYearInstant | 474674000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 1893578000 | JPY |
| Noncurrent liabilities | CurrentYearInstant | 2087632000 | JPY |
| Liabilities | Prior1YearInstant | 6597556000 | JPY |
| Liabilities | CurrentYearInstant | 7310586000 | JPY |
| Capital stock | Prior1YearInstant | 1535409000 | JPY |
| Capital stock | CurrentYearInstant | 1535409000 | JPY |
| Capital surplus | Prior1YearInstant | 1702732000 | JPY |
| Capital surplus | CurrentYearInstant | 1702732000 | JPY |
| Retained earnings | Prior1YearInstant | 7389420000 | JPY |
| Retained earnings | CurrentYearInstant | 9079131000 | JPY |
| Treasury stock | Prior1YearInstant | -175703000 | JPY |
| Treasury stock | CurrentYearInstant | -175947000 | JPY |
| Shareholders equity | Prior1YearInstant | 10451859000 | JPY |
| Shareholders equity | CurrentYearInstant | 12141325000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 137114000 | JPY |
| Valuation difference on available for sale securities | CurrentYearInstant | 158376000 | JPY |
| Foreign currency translation adjustment | Prior1YearInstant | 119184000 | JPY |
| Foreign currency translation adjustment | CurrentYearInstant | 162373000 | JPY |
| Remeasurements of defined benefit plans | Prior1YearInstant | 60618000 | JPY |
| Remeasurements of defined benefit plans | CurrentYearInstant | 196499000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | 316917000 | JPY |
| Valuation and translation adjustments | CurrentYearInstant | 517248000 | JPY |
| Non controlling interests | Prior1YearInstant | 47463000 | JPY |
| Non controlling interests | CurrentYearInstant | 53533000 | JPY |
| Net assets | Prior1YearInstant | 10816240000 | JPY |
| Net assets | CurrentYearInstant | 12712107000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 17413797000 | JPY |
| Liabilities and net assets | CurrentYearInstant | 20022694000 | JPY |
| Net sales | Prior1YearDuration | 23519516000 | JPY |
| Net sales | CurrentYearDuration | 26183521000 | JPY |
| Cost of sales | Prior1YearDuration | 17143676000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |